The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Abbott Laboratories
Consulting or Advisory Role - Abbott Laboratories; Bristol-Myers Squibb; Merck Serono
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst)
Expert Testimony - Abbott Laboratories
Travel, Accommodations, Expenses - Bristol-Myers Squibb
FLORA-5/GOG3035: Frontline chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] versus chemotherapy (paclitaxel-carboplatin-placebo [PCP]) in patients with advanced epithelial ovarian cancer (EOC)—Phase III, double-blind, placebo-controlled, global, multinational study.
 
Angeles Alvarez Secord
Honoraria - Myriad Genetics
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Eisai (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immutep (Inst); Merck (Inst); OncoQuest Pharmaceuticals (Inst); PharmaMar (Inst); Seagen (Inst); Tesaro (Inst); VBL Therapeutics (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline
(OPTIONAL) Uncompensated Relationships - Aravive; GOG Foundation; OncoQuest Pharmaceuticals; Regeneron; Roche/Genentech; VBL Therapeutics
 
Lisa Marie Barroilhet
Consulting or Advisory Role - AstraZeneca; Clovis Oncology
 
Myong Cheol Lim
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Boryung; GI Innovation; Takeda
Research Funding - AstraZeneca; CKD pharm; Clovis Oncology; OncoQuest
 
Sunil Gupta
Employment - Agenus; OncoQuest Pharmaceuticals
Leadership - Agenus
Stock and Other Ownership Interests - Agenus; Sanofi
Patents, Royalties, Other Intellectual Property - I received 3 patents on method of use for cabazitaxel (Jevtana( for patients with mCRPC who have been previously treated with docetaxel while employed with Sanofi Inc. The rights to the patients were transferred to Sanofi and I receive no compensation or
Travel, Accommodations, Expenses - Agenus
 
Sonia Oosman
Employment - OncoQuest Pharmaceuticals
 
Jada Srinivas Rao
Consulting or Advisory Role - OncoQuest Pharmaceuticals
 
John O. Schorge
No Relationships to Disclose
 
Joyce N. Barlin
Honoraria - AstraZeneca; Merck
Consulting or Advisory Role - Clovis Oncology
Speakers' Bureau - AstraZeneca; Merck
 
Lucy Gilbert
Honoraria - AstraZeneca; Eisai; GlaxoSmithKline; Merck; Merck/Eisai
Consulting or Advisory Role - GlaxoSmithKline; Merck
Research Funding - Alkermes (Inst); AstraZeneca (Inst); Esperas Pharma (Inst); Immunogen (Inst); IMV (Inst); Karyopharm Therapeutics (Inst); Merck Sharp & Dohme (Inst); Mersana (Inst); Novocure (Inst); OncoQuest (Inst); Roche (Inst); Tesaro/GSK (Inst)
 
Devansu Tewari
No Relationships to Disclose
 
Michael Gold
No Relationships to Disclose
 
Diane M. Provencher
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline
Research Funding - Abbvie; AstraZeneca
 
JUNG-YUN LEE
Consulting or Advisory Role - AstraZeneca; MSD; Roche; Takeda
Research Funding - AstraZeneca; Clovis Oncology (Inst); Immunogen (Inst); Janssen Oncology (Inst); Merck (Inst); MSD; MSD (Inst); Synthon (Inst)
 
Kristin Leigh Bixel
Consulting or Advisory Role - Merck
Research Funding - Intuitive Surgical
 
Eduardo Yañez
No Relationships to Disclose
 
Lukas Rob
No Relationships to Disclose
 
David M. O'Malley
Consulting or Advisory Role - Abbvie; Agenus; Ambry Genetics; Arcus Biosciences; Arquer Diagnostics; AstraZeneca; Atossa Therapeutics; BBI Healthcare; Celsion; Clovis Oncology; Eisai; Elevar Therapeutics; Genelux; Genentech/Roche; GlaxoSmithKline; GOG Foundation; Immunogen; InxMed; Iovance Biotherapeutics; Janssen Oncology; Laekna Therapeutics; Leap Therapeutics; Marker Therapeutics; Myriad Genetics; Novartis; Novocure; Novocure; Onconova Therapeutics; OncoQuest; Regeneron; Roche; Rubius Therapeutics; Seagen; Sorrento Therapeutics; Sutro Biopharma; Takeda; Tarveda Therapeutics; Tesaro; Toray Industries; Translational Genomics Research Institute; VBL Therapeutics; Vincerx Pharma
Research Funding - Abbvie (Inst); Abbvie/Stemcentrx (Inst); Acerta Pharma (Inst); Advaxis (Inst); Ajinomoto (Inst); Ajinomoto (Inst); Amgen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BBI Healthcare (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Clovis Oncology (Inst); Deciphera (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Ergomed (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Immunogen (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Janssen Research & Development (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Mersana (Inst); Novartis (Inst); NovoCure (Inst); OncoQuest (Inst); Pfizer (Inst); PharmaMar (Inst); Precision Therapeutics (Inst); Regeneron (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Sumitomo Dainippon Pharma Oncology, Inc. (Inst); Sutro Biopharma (Inst); Tesaro (Inst); TRACON Pharma (Inst); Verastem (Inst)